AR067107A1 - Derivados de tiazol[5,4-b]piridin moduladores de sirtuinas - Google Patents

Derivados de tiazol[5,4-b]piridin moduladores de sirtuinas

Info

Publication number
AR067107A1
AR067107A1 ARP080102663A ARP080102663A AR067107A1 AR 067107 A1 AR067107 A1 AR 067107A1 AR P080102663 A ARP080102663 A AR P080102663A AR P080102663 A ARP080102663 A AR P080102663A AR 067107 A1 AR067107 A1 AR 067107A1
Authority
AR
Argentina
Prior art keywords
diseases
disorders
sirtuins
heterocycle
optionally substituted
Prior art date
Application number
ARP080102663A
Other languages
English (en)
Spanish (es)
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of AR067107A1 publication Critical patent/AR067107A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP080102663A 2007-06-20 2008-06-20 Derivados de tiazol[5,4-b]piridin moduladores de sirtuinas AR067107A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93663607P 2007-06-20 2007-06-20

Publications (1)

Publication Number Publication Date
AR067107A1 true AR067107A1 (es) 2009-09-30

Family

ID=39798234

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102663A AR067107A1 (es) 2007-06-20 2008-06-20 Derivados de tiazol[5,4-b]piridin moduladores de sirtuinas

Country Status (23)

Country Link
US (2) US7893086B2 (OSRAM)
EP (1) EP2170905A2 (OSRAM)
JP (1) JP5498940B2 (OSRAM)
KR (1) KR20100051048A (OSRAM)
CN (2) CN103833775A (OSRAM)
AR (1) AR067107A1 (OSRAM)
AU (1) AU2008266749C1 (OSRAM)
BR (1) BRPI0813651A2 (OSRAM)
CA (1) CA2691733A1 (OSRAM)
CL (1) CL2008001822A1 (OSRAM)
CO (1) CO6251248A2 (OSRAM)
CR (1) CR11232A (OSRAM)
DO (1) DOP2009000284A (OSRAM)
EA (1) EA018922B1 (OSRAM)
IL (1) IL202730A0 (OSRAM)
MA (1) MA31506B1 (OSRAM)
MX (1) MX2009013977A (OSRAM)
NZ (1) NZ581990A (OSRAM)
PE (1) PE20090694A1 (OSRAM)
TW (1) TW200916472A (OSRAM)
UY (1) UY31169A1 (OSRAM)
WO (1) WO2008156869A2 (OSRAM)
ZA (1) ZA200908883B (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2618370A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
US8293747B2 (en) * 2007-07-19 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
AU2008325148A1 (en) * 2007-11-08 2009-05-14 Sirtris Pharmaceuticals, Inc. Solubilized thiazolopyridines
CA2723135A1 (en) 2008-05-01 2009-11-05 Sirtris Pharmaceuticals, Inc. Quenolines and related analogs as sirtuin modulators
CN104193740A (zh) 2008-07-03 2014-12-10 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
KR101679089B1 (ko) 2008-09-29 2016-11-23 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 크로메논 유사체
EP2367563A4 (en) 2008-12-08 2012-12-19 Univ Northwestern PROCESS FOR HSF-1 MODULATION
UA104447C2 (uk) * 2008-12-19 2014-02-10 Сіртріз Фармасьютікалз, Інк. Тіазолопіридинові сполуки, що модулюють сиртуїн
EP2493888B1 (en) 2009-10-29 2016-04-06 GlaxoSmithKline LLC Bicyclic pyridines and analogs as sirtuin modulators
WO2011119869A1 (en) * 2010-03-24 2011-09-29 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
EP2993236A1 (en) * 2010-04-15 2016-03-09 Glaxosmithkline LLC Sirtuin activators and activation assays
EP2957636B1 (en) * 2010-05-03 2020-04-01 CuRNA, Inc. Treatment of sirtuin 3 (sirt3) related diseases by inhibition of natural antisense transcript to sirt3
TW201223956A (en) 2010-08-13 2012-06-16 Solvay Light emitting materials for electronics
EP2423214A1 (en) 2010-08-13 2012-02-29 Solvay SA Light emitting materials for Electronics
KR20120047341A (ko) * 2010-10-21 2012-05-14 경상대학교산학협력단 니코틴아미드를 유효성분으로 포함하는 알킬화 약물-유도성 신경퇴행의 예방 또는 치료용 조성물
US20130338178A1 (en) 2011-02-02 2013-12-19 The Trustees Of Princeton University Sirtuin modulators as inhibitors of cytomegalovirus
KR101329524B1 (ko) 2011-05-23 2013-11-13 연세대학교 산학협력단 미분화 전능성 줄기세포의 선택적 세포사멸 방법
SG10201609673QA (en) 2011-07-15 2017-01-27 Numeta Sciences Inc Compositions And Methods For Modulating Metabolic Pathways
US10342814B2 (en) * 2011-09-07 2019-07-09 Cornell University Methods for treatment of cancer by targeting Sirt5
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
KR20150082623A (ko) 2012-11-13 2015-07-15 뉴서트 사이언시스, 인크. 에너지 대사를 증가시키기 위한 조성물 및 방법
JP6550370B2 (ja) 2013-03-15 2019-07-24 ニューサート サイエンシーズ， インコーポレイテッド 脂質レベルを低下させるロイシンおよびニコチン酸
US9724319B2 (en) 2014-02-27 2017-08-08 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
WO2015143654A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
US10316054B2 (en) 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
EP3152220A1 (en) 2014-06-06 2017-04-12 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CN107496410A (zh) * 2017-09-21 2017-12-22 上海华堇生物技术有限责任公司 洋槐黄素的药物用途
EP3700334A4 (en) * 2017-10-27 2021-07-21 Transfusion Health, LLC COMPOSITIONS AND PROCESS FOR PRODUCING EXPANDED HEMATOPOETIC STEM CELLS USING FLUORENE DERIVATIVES
KR20200133747A (ko) 2018-02-20 2020-11-30 인사이트 코포레이션 암을 치료하기 위한 hpk1 억제제로서의 n-(페닐)-2-(페닐)피리미딘-4-카복스아미드 유도체 및 관련 화합물
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
JP2022543155A (ja) 2019-08-06 2022-10-07 インサイト・コーポレイション Ｈｐｋ１阻害剤の固体形態
EP4514768A2 (en) * 2022-04-29 2025-03-05 The Regents of the University of Michigan Small molecule sirtuin inhibitors and uses thereof

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164603A (en) * 1965-01-05 xnhcox
DE1108698B (de) 1959-09-03 1961-06-15 Hoechst Ag Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen
FR1439129A (fr) 1965-04-02 1966-05-20 Chimetron Nouveaux sulfonylbenzimidazoles
FR1476529A (fr) 1965-04-24 1967-04-14 Chimetron Sarl Nouveaux dérivés benzimidazole-sulfoniques et sulfamides correspondants
FR1450625A (fr) 1965-06-18 1966-06-24 Chimetron Sarl Sulfonamidothiazolyl-2 benzimidazoles
US3503929A (en) * 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
US3517007A (en) * 1968-04-05 1970-06-23 American Home Prod 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds
US3928228A (en) * 1969-04-28 1975-12-23 Sterling Drug Inc 4,4{40 -Stilbenebis-pyridooxazoles and related optical brighteners and polymeric compositions brightened thereby
US3712888A (en) * 1970-12-14 1973-01-23 American Cyanamid Co Bis-pyridoxazole-stilbene derivatives for optical brightening
CA1006165A (en) 1971-04-06 1977-03-01 Eastman Kodak Company Ballasted color photographic couplers
AR208500A1 (es) 1972-06-14 1977-02-15 Merck & Co Inc Procedimiento para la preparacion de derivados de oxazolo(4,5-b)-piridinas
US4038396A (en) * 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
PL96241B1 (pl) 1975-06-30 1977-12-31 Sposob wytwarzania 2-/2-podstawionych-4-tiazolilo/-benzimidazoli
JPS6040016B2 (ja) * 1977-08-31 1985-09-09 コニカ株式会社 マゼンタ色素画像の形成方法
US4471040A (en) * 1980-09-10 1984-09-11 Canon Kabushiki Kaisha Electrophotographic disazo photosensitive member
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4939133A (en) * 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
DE3807084A1 (de) 1988-03-04 1989-09-14 Knoll Ag Neue benzimidazo(1,2-c)chinazoline, ihre herstellung und verwendung
JPH04190232A (ja) 1990-11-26 1992-07-08 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH04191736A (ja) 1990-11-27 1992-07-10 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
JPH06247969A (ja) 1992-12-28 1994-09-06 Takeda Chem Ind Ltd 縮合複素環化合物及びそれを含む農園芸用殺虫剤
US5852011A (en) * 1994-05-31 1998-12-22 Mitsui Chemicals, Inc. Benzimidazole derivatives
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
AUPN449295A0 (en) 1995-07-28 1995-08-24 Inner And Eastern Health Care Network, The Radioprotectors
AU6966696A (en) * 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5808087A (en) * 1995-11-29 1998-09-15 Mitsui Chemicals, Inc. Sulfonium salts of pyrrolylbenzimidazoles
WO1999033824A1 (en) 1997-12-31 1999-07-08 Rutgers, The State University Of New Jersey Heterocyclic topoisomerase poisons
HUP0102981A3 (en) * 1998-03-31 2002-10-28 Shionogi & Co Pyrrolo[1,2-a]pyrazine derivatives and pharmaceutical compositions thereof
ES2237966T3 (es) 1998-08-20 2005-08-01 Agouron Pharmaceuticals, Inc. Agentes de gnrh no peptidicos, metodos y compuestos intermedios para su preparacion.
US6653309B1 (en) * 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
EP1177188B1 (en) 1999-05-12 2005-10-12 Ortho-McNeil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
CA2377085C (en) 1999-06-23 2011-02-15 Aventis Pharma Deutschland Gmbh Substituted benzimidazoles
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
AU2001258784A1 (en) 2000-05-22 2001-12-03 Takeda Chemical Industries Ltd. Tyrosine phosphatase inhibitors
BR0111544A (pt) 2000-06-14 2003-07-01 Warner Lambert Co Heterociclos bicìclicos 6,5-fundidos
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP2002161084A (ja) 2000-11-28 2002-06-04 Sumitomo Pharmaceut Co Ltd 複素環誘導体
US20040010033A1 (en) * 2001-02-20 2004-01-15 Pfizer Inc. Non-peptide GnRH agents, methods and intermediates for their preparation
WO2002066454A1 (fr) 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
KR20030083016A (ko) 2001-03-28 2003-10-23 브리스톨-마이어스스퀴브컴파니 신규 타이로신 카이나제 억제제
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US6716866B2 (en) 2001-06-13 2004-04-06 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
MXPA04000803A (es) 2001-07-27 2004-05-21 Curis Inc Mediadores de rutas de senalizacion de hedgehog, composiciones y usos relacionados a los mismos.
WO2004043335A2 (en) * 2001-09-13 2004-05-27 Genesoft, Inc. Methods of treating infection by drug resistant bacteria
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
US7622479B2 (en) 2001-11-26 2009-11-24 Takeda Pharmaceutical Company Limited Bicyclic derivative, its production and use
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
KR100875362B1 (ko) 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
CA2475633C (en) 2002-02-06 2013-04-02 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
WO2003078397A1 (en) * 2002-03-18 2003-09-25 Merck Frosst Canada & Co. Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
CA2479338A1 (en) 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP4239463B2 (ja) 2002-04-09 2009-03-18 大正製薬株式会社 ３−トリフルオロメチルアニリド誘導体
JP4224979B2 (ja) 2002-04-09 2009-02-18 大正製薬株式会社 インターロイキン１２抑制剤
CN100360130C (zh) * 2002-04-18 2008-01-09 先灵公司 用作组胺h3拮抗剂的1－(4－哌啶基)苯并咪唑酮
JP2003313176A (ja) 2002-04-24 2003-11-06 Sankyo Co Ltd アミノアゾール誘導体
AU2003242137A1 (en) 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc Medicament for treatment of diabetes
AU2003249937A1 (en) * 2002-07-12 2004-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
AU2003254650B2 (en) 2002-07-24 2010-09-09 Qlt, Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP2004075614A (ja) 2002-08-20 2004-03-11 Sankyo Co Ltd クロメン誘導体を含有する医薬
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US20040171073A1 (en) * 2002-10-08 2004-09-02 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
BR0315158A (pt) * 2002-10-09 2005-08-16 Pfizer Prod Inc Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
AU2003299378A1 (en) 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2004039318A2 (en) 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
US7622592B2 (en) * 2002-11-01 2009-11-24 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
AU2003302497A1 (en) * 2002-11-27 2004-06-23 Ph. D. Edward M. Eddy Glyceraldehyde 3-phosphate dehydrogenase-s(gapds), a glycolytic enzyme expressed only in male germ cells,is a target for male contraception
DE10300398A1 (de) 2003-01-09 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel
WO2004069160A2 (en) 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
AU2004212490B2 (en) * 2003-02-10 2008-05-15 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
ES2502490T3 (es) * 2003-02-26 2014-10-03 Sugen, Inc. Compuestos aminoheteroarílicos como inhibidores de proteín quinasas
EP1606267B1 (en) * 2003-03-11 2008-07-30 Pfizer Products Inc. Pyrazine compounds as transforming growth factor (tgf) inhibitors
US7459454B2 (en) 2003-03-21 2008-12-02 Smithkline Beecham Corporation Aminopyrazine derivatives and compositions
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
ES2293324T3 (es) 2003-09-12 2008-03-16 4 Aza Ip Nv Derivados de pteridina para el tratamiento de enfermedades relativas al tnf-alpha.
GB2405793A (en) 2003-09-12 2005-03-16 4 Aza Bioscience Nv Pteridine derivatives for treating TNF-alpha related disorders
CN1871244A (zh) * 2003-09-19 2006-11-29 弗·哈夫曼-拉罗切有限公司 作为腺苷受体配体的噻唑并吡啶衍生物
JP4795634B2 (ja) 2003-10-31 2011-10-19 出光興産株式会社 有機薄膜トランジスタ
JP2005162855A (ja) 2003-12-02 2005-06-23 Konica Minolta Holdings Inc 着色組成物、インクジェット記録用インク、カラートナー、光記録媒体、感熱転写記録材料用インクシート、カラーフィルター、及び該インクジェット記録用インクを用いたインクジェット記録方法
ES2346323T3 (es) 2004-02-11 2010-10-14 Basilea Pharmaceutica Ag Bencimidazoles sustituidos y su uso para inducir apoptosis.
WO2005100342A1 (en) * 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
CA2810655C (en) * 2004-06-24 2013-12-10 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
BRPI0515012A (pt) 2004-08-13 2008-07-01 Genentech Inc substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
DE102004039789A1 (de) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
NZ555419A (en) 2004-11-03 2009-07-31 Curis Inc Mediators of the hedgehog gene signaling pathways, compositions and uses related thereto
CA2586870A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
JP4635633B2 (ja) 2005-02-04 2011-02-23 横浜ゴム株式会社 空気入りタイヤおよびその製造方法
AU2006218404A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CA2618370A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
US7935957B2 (en) * 2005-08-12 2011-05-03 Semiconductor Energy Laboratory Co., Ltd. Memory device and a semiconductor device
JP4191736B2 (ja) 2006-01-11 2008-12-03 日本電信電話株式会社 電界通信システム
BRPI0808523A2 (pt) 2007-03-01 2014-08-19 Novartis Vaccines & Diagnostic Inibidores de pim cinase e métodos de seu uso
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
CL2008001821A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
US20100168084A1 (en) * 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use

Also Published As

Publication number Publication date
CA2691733A1 (en) 2008-12-24
EA018922B1 (ru) 2013-11-29
MA31506B1 (fr) 2010-07-01
EA201070035A1 (ru) 2010-06-30
JP2010530432A (ja) 2010-09-09
PE20090694A1 (es) 2009-06-20
JP5498940B2 (ja) 2014-05-21
CR11232A (es) 2010-05-24
US8268862B2 (en) 2012-09-18
AU2008266749A1 (en) 2008-12-24
CN103833775A (zh) 2014-06-04
UY31169A1 (es) 2009-01-30
AU2008266749B2 (en) 2012-03-15
CN101801981A (zh) 2010-08-11
WO2008156869A3 (en) 2009-05-14
DOP2009000284A (es) 2010-02-28
NZ581990A (en) 2012-07-27
MX2009013977A (es) 2010-04-09
ZA200908883B (en) 2010-08-25
CL2008001822A1 (es) 2009-03-13
CO6251248A2 (es) 2011-02-21
US20090105246A1 (en) 2009-04-23
KR20100051048A (ko) 2010-05-14
US7893086B2 (en) 2011-02-22
TW200916472A (en) 2009-04-16
AU2008266749C1 (en) 2012-11-01
BRPI0813651A2 (pt) 2014-12-30
US20110152254A1 (en) 2011-06-23
EP2170905A2 (en) 2010-04-07
IL202730A0 (en) 2010-06-30
WO2008156869A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
AR067107A1 (es) Derivados de tiazol[5,4-b]piridin moduladores de sirtuinas
AR067106A1 (es) Derivados de imidazo[2,1-b]tiazol moduladores de sirtuina
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
CR20110353A (es) Compuestos de tiazolopiridina moduladores de sirtuina referencia cruzada
EA201070551A1 (ru) Сиртуинмодулирующие соединения
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
DOP2012000124A (es) Derivados de la cromenona con actividad anti-tumoral
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
EA201070579A1 (ru) Солюбилизированные тиазолопиридины
AR077999A1 (es) Antagonistas de pirimidin y triazin-hepcidina
UY30835A1 (es) 8-alquinilxantinas y derivados
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
AU2014265671A8 (en) Substituted bridged urea analogs as sirtuin modulators
UY30856A1 (es) Nuevos derivados de 2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y principalmente como inhibidores de ikk
CO2017004994A2 (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
PE20191032A1 (es) Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
AR057906A1 (es) Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta.
AR077124A1 (es) Agentes antihelminticos y su uso
ECSP088826A (es) Compuestos heterocíclicos apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5ht6
AR077958A1 (es) Quinoxalinonas antagonistas de la hepcidina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal